title: Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.
abstract: OBJECTIVE
  To examine neurological and magnetic resonance imaging (MRI) changes following discontinuation of interferon (IFN)-beta-1a treatment in secondary progressive multiple sclerosis (SPMS).
  
  
  METHODS
  The study involved 21 SPMS patients who received subcutaneous (s.c.) IFN-beta-1a 44 microg three times weekly (t.i.w.) for 12 months and were thereafter followed up without treatment for a further 12 months. The number of relapses, disability on the Expanded Disability Status Scale (EDSS) and MRI were recorded at baseline, at 12 months of IFN-beta-1a 44 microg t.i.w. and 1 year after discontinuation of treatment.
  
  
  RESULTS
  During the 12-month treatment EDSS score and volumes of brain T2- and T1-weighted lesions remained without significant progression, but at 12 months after treatment discontinuation both EDSS score and the volumes of cerebral lesions increased significantly. Cerebrospinal fluid fraction increased significantly both during the treatment and during follow-up.
  
  
  CONCLUSIONS
  Discontinuation of IFN-beta-1a 44 microg t.i.w. in SPMS may be associated with an increase in neurological disability and brain lesions on MRI.
authors.affiliation: Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland.
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: P
authors.initials: P
authors.lastname: Dastidar
authors.forename: H
authors.initials: H
authors.lastname: Kuusisto
authors.forename: M
authors.initials: M
authors.lastname: Ukkonen
authors.forename: H
authors.initials: H
authors.lastname: Huhtala
authors.forename: I
authors.initials: I
authors.lastname: Elovaara
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D001284:Atrophy; D001921:Brain / Q000473:pathology; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000473:pathology*; D012008:Recurrence
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a